Get notified of page updates

Clinicaltrials.gov identifier:
NCT04115306

Study Contact Information:

For more information about the study, visit https://phoenixmd.ca/clinical-trials.

PRINTER FRIENDLY PAGE

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Phoenix Molecular Designs

Clinicaltrials.gov identifier:
NCT04115306

Study Contact Information:

For more information about the study, visit https://phoenixmd.ca/clinical-trials.

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

PMD-026 is a study for people who have been diagnosed with triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC.  NOTE: This study is no longer enrolling. 

 

This Study is Open To:

NOTE: This study is no longer enrolling. 

This Study is NOT Open To:

NOTE: This study is no longer enrolling. 

Study Contact Information:

For more information about the study, visit https://phoenixmd.ca/clinical-trials.